Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus

Glycemic control is limited by the barrier of hypoglycemia. Recurrent hypoglycemia impairs counterregulatory (CR) hormone responses to subsequent hypoglycemia.

[1]  R. Beck,et al.  Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes , 2013, Diabetes Care.

[2]  T. Jones,et al.  Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes , 2012, Diabetes Care.

[3]  R. Beck,et al.  Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function , 2012, Diabetes Care.

[4]  P. Cryer.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. , 2012, Endocrinology.

[5]  P. Cryer.  Death during intensive glycemic therapy of diabetes: mechanisms and implications. , 2011, The American journal of medicine.

[6]  A. Arbeláez,et al.  Glucose counterregulatory responses to hypoglycemia. , 2011, Pediatric endocrinology reviews : PER.

[7]  V. Basevi.  Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[8]  A. Classification,et al.  Standards of Medical Care in Diabetes—2009 , 2009, Diabetes Care.

[9]  P. Cryer.  The Barrier of Hypoglycemia in Diabetes , 2008, Diabetes.

[10]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[11]  P. Donnan,et al.  Frequency and predictors of hypoglycaemia in Type 1 and insulin‐treated Type 2 diabetes: a population‐based study , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[12]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[13]  P. Cryer,et al.  External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. , 1985, The Journal of laboratory and clinical medicine.

[14]  P. Cryer,et al.  Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. , 1983, The New England journal of medicine.

[15]  P. Brunetti,et al.  Abnormal Glucose Counterregulation in Insulin-dependent Diabetes Mellitus: Interaction of Anti-Insulin Antibodies and Impaired Glucagon and Epinephrine Secretion , 1983, Diabetes.

[16]  J. Gerich,et al.  Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect , 1973, Science.

[17]  UK Prospective Diabetes Study Group.  Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration , 2007, Diabetologia.

[18]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[19]  D. Becker,et al.  Impaired Counterregulatory Hormone Responses to Hypoglycemia in Children and Adolescents with New Onset IDDM , 1994, The Journal of pediatric endocrinology.

[20]  D. Becker,et al.  Abnormal Alpha Cell Hypoglycemic Recognition in Children with Insulin Dependent Diabetes Mellitus (IDDM) , 1994, The Journal of pediatric endocrinology.

[21]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.